A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-15

Study Completion Date

2017-07-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate MEDI6383 when given alone or together with MEDI4736 in adult subjects with recurrent or metastatic solid tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

NCT01633970

Cancer

COMPLETED PHASE1

Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors

NCT00263783

Cancer

COMPLETED PHASE1

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

NCT02705482

Select Advanced Solid Tumors

COMPLETED PHASE1

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

NCT00923195

Melanoma Skin Cancer

COMPLETED PHASE2

A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

NCT03946800

Solid Tumors Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 1, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and antitumor activity of MEDI6383 alone and in combination with MEDI4736 in adult subjects with recurrent or metastatic solid tumors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent or Metastatic Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Monotherapy Arm

MEDI6383

Group Type EXPERIMENTAL

MEDI6383

Intervention Type BIOLOGICAL

Subjects will receive MEDI6383 until disease progression or adverse event.

Combination Arm

MEDI6383 and MEDI4736

Group Type EXPERIMENTAL

MEDI6383 and MEDI4736

Intervention Type BIOLOGICAL

Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MEDI6383

Subjects will receive MEDI6383 until disease progression or adverse event.

Intervention Type BIOLOGICAL

MEDI6383 and MEDI4736

Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female subjects; age ≥ 18
2. Written informed consent must be obtained
3. Subjects must meet the following criteria:

1. Have recurrent or metastatic solid tumors
2. Must have received and have progressed, are refractory, or are intolerant to standard therapy appropriate for the specific tumor type. Subjects should not have received more than 5 prior lines of therapy for recurrent or metastatic disease including both standards of care and investigational therapies
4. Subjects must have at least 1 lesion
5. Subjects must consent to provide archived tumor specimens and / or tumor biopsy for correlative biomarker studies.
6. Eastern Cooperative Oncology Group performance score of 0 or 1
7. In the opinion of the invesgator likely to complete ≥ 8 weeks of treatment.
8. Adequate organ function as determined by:

i. Absolute neutrophil count ≥ 1.5 x 109/L (1,500/mm3) ii.Platelet count ≥ 100 x 109/L (100,000/mm3) iii.Hemoglobin ≥ 9.0 g/dL within first 2 weeks prior to first dose of investigational product iv.Calculated creatinine clearance\* (CrCl) or 24 hour urine CrCl \> 50 mL/min v.Total bilirubin ≤ 1.5× ULN; for subjects with documented/suspected Gilbert's disease, bilirubin ≤ 3× ULN vi.Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5× ULN vii.Serum Electrolytes within normal limits
9. Females of childbearing potential who are sexually active with a nonsterilized male partner must use 2 methods of highly effective contraception from screening, and must agree to continue using such precautions for 90 days after the final dose of investigational product; 10) Nonsterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception from Day 1 through 90 days after receipt of the final dose of investigational product

Exclusion Criteria

1. Prior treatment with TNFRSF agonists including OX40, CD27, CD137 (4-1BB), CD357 (GITR) .
2. Subjects who have received prior therapy with regimens containing CTLA-4, PDL-1, or PD-1 antagonists are NOT permitted to enroll unless all of the following apply:

* Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy
* All AEs while receiving prior immunotherapy must have resolved to ≤ Grade 1 or baseline prior to screening for this study.
3. Must not have experienced a ≥ Grade 3 AE or neurologic or ocular AE of any grade while receiving prior immunotherapy
4. History of severe allergic reactions to any unknown allergens or any components of the study drug formulations
5. Active or prior documented autoimmune disease within the past 2 years.
6. Untreated central nervous system metastatic disease l
7. Concurrent enrollment in another clinical study, unless it is an observational (non interventional) clinical study or the follow-up period of an interventional study
8. Receipt of anticancer therapy within 28 days prior to the first dose of Investigational Product
9. Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment.
10. Unresolved toxicities from prior anticancer therapy
11. Systemic anticoagulation or daily aspirin dose exceeding 325 mg per day
12. Current or prior use of immunosuppressive medication within 14 days prior to the first dose of MEDI6383. )
13. History of primary immunodeficiency, solid organ transplantation, or tuberculosis
14. True positive test results for human immunodeficiency virus (HIV) or hepatitis B or C
15. Receipt of live, attenuated vaccine within 28 days prior to the first dose of investigational products )
16. Pregnant or breastfeeding women
17. Major surgery (as defined by the investigator) within 4 weeks prior to first dose of MEDI6383 or still recovering from prior surgery. Local surgery of isolated lesions for palliative intent is acceptable
18. Other invasive malignancy within 2 years

\-

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No